BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Chicago-Based Celsis International PLC  (CEL.L) Goes Private


10/12/2009 8:09:02 AM

CHICAGO, Oct. 9 /PRNewswire/ -- Chicago-based Celsis International, a leading global life sciences company, announces today that it has completed its public-to-private transaction process and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.

"Celsis has a very strong track record of consistent revenue and mid-teens profit growth, yet our strong financial results were not being reflected in our share price," explains Jay LeCoque, CEO of Celsis. "It is important to our future--both to our large customer base and to our employees here in Chicago and around the world--that we are able to continue to invest in and grow the business. Going private allows us the ability to focus more on our long term strategic growth opportunities." Celsis has been acquired by UK-based private equity firm JO Hambro, which has retained Mr. LeCoque and Christian Madrolle, Celsis' CFO, in their current management and Board positions.

Founded by serial entrepreneur Sir Christopher Evans, Celsis was floated on the LSE in 1993 and was a member of the techMARK Mediscience index. Named best performing share in 2003, the company consistently posted mid-teens profit growth numbers and has been profitable since 2001.

Celsis products and services deliver substantial time and cost savings to major pharmaceutical and consumer product companies while ensuring product quality and safety for consumers. Its customers include all of the top 25 pharma companies and Fortune 50 consumer product companies. Celsis employs 40 people in Chicago and another 200 worldwide. Its divisions include: Celsis Rapid Detection, the world leader in rapid microbial testing for industry; Celsis Analytical Services, providing cost effective analytical laboratory testing services to pharmaceutical and consumer product manufacturers; and Celsis In Vitro Technologies, a pioneer and leader of in vitro ADME-Tox products used to reduce the cost of drug discovery and development.

More information is online at celsis.com.

SOURCE Celsis International

CONTACT: Jay LeCoque, CEO or Robyn LaLonde, Executive Assistant to CEO,
both of Celsis International, +1-312-476-1200

Web site: http://www.celsis.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES